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Abstract: IFNL3, which encodes interferon-k3 (IFN-k3), has received
considerable attention in the hepatitis C virus (HCV) ﬁeld, as many
independent genome-wide association studies have identiﬁed a
strong association between polymorphisms near IFNL3 and clearance
of HCV. However, the mechanism underlying this association has
remained elusive. In this study, we report the identiﬁcation of a func-
tional polymorphism (rs4803217) in the 30 untranslated region
(UTR) of IFNL3 mRNA that dictated transcript stability. We found
that this polymorphism inﬂuenced AU-rich element (ARE)-mediated
decay (AMD) of IFNL3 mRNA, as well as the binding of HCV-induced
microRNAs during infection. Together these pathways mediated
robust repression of the unfavorable IFNL3 polymorphism. Our data
reveal a previously unknown mechanism by which HCV attenuates
the antiviral response and indicate new potential therapeutic targets
for HCV treatment.
Open access under CC BY-NC-ND license. 2014 European Association for the Study of the Liver. Published
by Elsevier B.V.
While direct acting antivirals for hepatitis C virus (HCV) infec-
tion become available in some countries, interferon (IFN)-based
regimen remains an option for many patients worldwide [1]. A
strong association has been observed between polymorphisms
located within the IFNL3 locus (IL28B) and the response to IFN-
based therapy [2–4]. Nevertheless, until now no mechanism
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variants.
Several studies have shown an association between favourable
and unfavourable polymorphisms and IFNL3 expression in blood
and PBMCs from individuals carrying theminor alleles [3,4]. How-
ever this association was not demonstrated in infected hepato-
cytes, stimulated hepatocytes, and infected individuals [5,6],
and this association remains controversial. Prokunina et al. have
shown that a dinucleotide frame shift variant ss469415590,
located upstream of IFNL3, generates a transcript encoding the
IFN-k4 protein [7]. This is a protein with a 40% amino acidic sim-
ilarity to INF-k3. The presence of the dinucleotide variant that
allows the expression of IFN-k4 was associated with a reduced
clearance of the virus [7]. Whereas recombinant IFNL4 showed
antiviral activity against HCV, it remains a paradox why the
presence of IFNL4 is a disadvantage for patients with HCV [8].
In the January 2014 issue of Nature Immunology, McFarland
et al. presented a novel strategy by which HCV reduces the IFNL3
expression through the induction of two miRNAs that target the
30UTR region of the unfavourable IFNL3 variant [9]. The authors
identiﬁed a genomic variant in the 30 untranslated region (UTR)
of IFNL3 that determines the IFNL3 mRNA stability and subse-
quent IFN-k3 expression during HCV infection. A thymidine (T)
to guanine (G) variation in this region results in a favourable phe-
notype of sustained virological response (SVR) in HCV-infected
patients. This polymorphism, rs4803217 impacts the mRNA
decay rate mediated by AU-rich elements and RISC (RNA-induced
silencing complex).The favourable T to G
A-U rich elements (AREs)-mediated decay (AMD) regulates
mRNA degradation by the binding of RNA degradative proteins
to the mRNA in speciﬁc ARE domains. These sites are often
present in cytokine mRNAs. McFarland et al. described three
functional AREs in the 30UTR region of the IFNL3. They observed
that the favourable IFNL3-G variant presents a higher mRNA
half-life than their unfavourable IFNL3-T counterpart.A myosin-linked microRNA regulation
MiRNAs can work together with ARE-binding proteins to induce
mRNA degradation [10]. In their study, McFarland et al. identiﬁed14 vol. 61 j 944–946
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two miRNAs (miR-208b and miR-499a-5p) induced by HCV
infection, with predicted binding sites at the 30UTR of the IFNL3
mRNA. These miRNAs belong to the ‘‘myomiRs’’, a group of
miRNAs localised and co-expressed with myosin-encoded genes.
Interestingly, the IFNL3 T-to-G polymorphism localises in the
miRNAs seed region and the authors reported that the induced-
expression of both miRNAs stimulated the IFNL3-T degradation
whereas the alternative IFNL3-G form was not subjected to this
control. Furthermore, HCV infection reduced the expression of
the IFNL3-T variant but not that of IFNL3-G.miRNA inhibition and viral clearance
The inhibition of miR-208b and miR-499a-5p, in an HCV-infected
cell line, rescued the IFNL3-T expression with no effect on the
IFNL3-G variant. Additionally, this increased IFNL3-T expression
was accompanied with a reduction in HCV copy numbers and
virus titer.
The authors complete their observation showing a signiﬁcant
increase in the expression of miR-208b in liver samples of HCV-
chronic infected patients. These results emphasise the relevance
of the work of McFarland et al. presenting viral-induced miRNAs
as a mechanism to dampen the host response. Until now, the
association between IFNL3 polymorphisms and its mRNA or
protein expression remained controversial. Based on McFarland’s
demonstration, patients with favourable IFNL3 polymorphism
would show increased expression of HCV-induced miRNAs, and
reduced protein expression of IFNL3. Further analyses will be4 
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Fig. 1. Schematic representation of molecular mechanisms behind IFNL3 and
IFNL4 polymorphisms. The polymorphism ss469415590 regulates the expres-
sion of IFNL4. The DG allele generates a splicing variant that allows the
expression of IFNL4 protein, while there is no protein expression with the TT
allele. The expression of IFN-k4 was associated with viral persistence. Regarding
the IFNL3 polymorphism, McFarland et al. described that HCV infection induces
the expression of two miRNAs (mir-2008b and mir-499a-5p). These two miRNAs
target the 30UTR of IFNL3 mRNA. In patients carrying the favourable rs4803217 G
genotype, these miRNAs cannot bind the IFNL3 mRNA sequence and therefore
cannot inhibit its expression. Conversely, in patients carrying the unfavourable
allele, the miRNAs can bind the IFNL3 mRNA and inhibit its expression by
inducing its degradation through the RISC complex. Additionally, the presence of
the favourable variant reduces the binding of ARE-binding proteins to the ARE
domains, impairing the degradation of the mRNA.
Journal of Hepatology 201needed to determine how the miRNAs, described by McFarland
et al., are acting in patients with chronic hepatitis C. A speciﬁc reg-
ulation of these miRNAsmay reconcile the controversial results of
the expression level of IFNL3 according to the different genotypes.
Moreover, miR-208b, and miR-499a-5p, may regulate the expres-
sion of genes encoding antiviral activity andmay contribute to the
antiviral state associated with the favourable IFNL3 genotype.
In contrast to previous studies that remained at the genomic
level [2–6], McFarland et al. went one step further and developed
in vitro assays to study the effects of these polymorphisms on
gene expression. They constructed reporters containing different
ﬂuorescent proteins for each of the genomic variants to address
simultaneously their expression. This methodology could be
applied for the study of other polymorphisms associated to
HCV clearance, or interestingly, to address their similar or differ-
ential effect in hepatitis B virus (HBV) infection.
Finally, McFarland et al. discuss the possibility of developing
an anti-miRNA therapy against HCV-induced myomiRs as a
promising alternative for patients carrying the IFNL3-T variant.
However considering the recent advances in anti-HCV therapies,
the beneﬁt of the development of anti-miRNAs encoded in myo-
sin genes may be limited. Interestingly, myomiRs expression can-
not be induced by any viral infection and seems to be speciﬁcally
associated with HCV. This ﬁnding may explain why IFN polymor-
phisms have not been associated with IFN-induced viral clear-
ance in other types of viral infection.
In conclusion, McFarland et al. provide an elegant study in
which they propose a novel molecular mechanism for the previ-
ously shown lower IFNL3 expression in patients carrying the
unfavourable allele. Together with the description of IFNL4, these
studies provide new insights into the molecular mechanisms
underlying the association between IFNL3 polymorphisms and
the response to treatment, in patients infected with HCV
(Fig. 1). These ﬁndings contribute to the understanding of the
HCV-host interactions, and the HCV mechanisms for viral eva-
sion. It remains to be established how other polymorphisms in
this locus [2–4], are contributing to the response to treatment,
and whether direct or indirect mechanisms are involved.Conﬂict of interest
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